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Abstract
Purpose: Locally recurrent rectal cancer may cause signiﬁcant morbidity. Prior reports of rectal
cancer reirradiation following local recurrence suggest treatment efﬁcacy, with variable rates of late
toxicity. Modern techniques including intensity modulated radiation therapy (IMRT) may improve
the therapeutic index. We report outcomes for pelvic reirradiation as treatment for rectal cancer
using IMRT.
Methods and materials: The records of 31 patients undergoing reirradiation for rectal cancer
between 2004 and 2013 were reviewed. All patients underwent IMRT using an accelerated
hyperfractionation (39 Gy in 1.5-Gy fractions delivered twice daily, nZ15) or once-daily
fractionation technique (median dose, 30.4 Gy; range, 27-40 Gy in 15-22 fractions; nZ 16). The
median cumulative dose was 77 Gy (range, 59-113), and the median interval from prior pelvic
radiation therapy was 39.8 months (range, 10.1-307.6). Treatment intent was palliative in 20
patients and neoadjuvant or adjuvant in 11 patients. Surgery was generally reserved for patients
with an isolated local recurrence. Concurrent chemotherapy was administered for 25/31 patients,
most frequently capecitabine (nZ11) or continuous infusion 5-ﬂuorouracil (nZ10).
Results: Median follow-up was 11.3 months. The prescribed treatment was completed in 29/31
patients (93.5%). Among 18 patients with symptoms attributable to recurrent disease, successful
palliation was achieved in 10/18 (55.6%). The rate of grade 2 and grade 3 acute toxicities was
32.3% and 3.2%, respectively. Local control rates at 1 and 2 years were 61.3% and 47.3%,
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respectively. Median overall survival was 21.9 months, and 1-year survival was 66.7% for patients
who had surgical resection versus 58.7% for those who did not (P Z .0802).
Conclusions: Rectal cancer reirradiation using IMRT is well-tolerated in the setting of prior pelvic
radiation therapy. Given signiﬁcant risk of local progression, further dose escalation may be
warranted for patients with life expectancy exceeding 1 year.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Locally recurrent rectal cancer may cause signiﬁcant
morbidity, including debilitating pelvic pain, rectal bleeding,
bowel obstruction, and sciatica, and has limited treatment
options. Previous studies show local recurrence rates
ranging from 4.4% to 11%.1-3 Prior reports of rectal cancer
reirradiation suggest treatment efﬁcacy, with variable rates
of late toxicity. Das et al described the use of hyper-
fractionated accelerated radiation therapy (RT; 39 Gy in 1.5-
Gy fractions twice daily) for palliative or neoadjuvant
treatment of rectal cancer in patients with prior pelvic ra-
diation therapy and demonstrated a 3-year rate of freedom
from local progression of 33%, overall survival rate of 39%,
and grade 3 to 4 late toxicity of 35%.4 Ng et al described a
once-daily fractionation of 39.6 Gy in 22 fractions and
demonstrated a median overall survival of 19 months, with
12.5% of patients experiencing grade 3 acute toxicity, no
grade 4 acute toxicity, and 1 late toxicity in a patient irra-
diated palliatively.5
Modern treatment techniques including intensity
modulated RT (IMRT) may improve the therapeutic index
of reirradiation. This retrospective study was conducted to
evaluate oncologic outcomes and toxicities for reirradia-




An institutional review board approved review of the
records of 31 patients with locally recurrent rectal cancer
treated with reirradiation between 2004 and 2013 at our
institution was performed. Prior extirpative resection of
rectal cancer was performed in 24 of the 31 patients, with
initial pathologic stage II (nZ12), III (nZ7), IV (nZ2),
or unknown (nZ3). For 6 of the 31 patients, prior local
treatment included chemo-RT alone (nZ4) or chemo-RT
with transanal excision (nZ2). A single patient under-
went prior neoadjuvant chemo-RT and deﬁnitive resec-
tion of a small bowel malignancy and was treated with
reirradiation neoadjuvantly for a new primary rectal
cancer. Prior pelvic RT was given as treatment for rectal
or rectosigmoid cancer in 27 of the 31 patients and as
treatment for other malignancies in 4 of the 31 patients
including prostate (nZ 2), endometrial (nZ1), and small
bowel (nZ1) malignancies. Patient characteristics are
shown in Table 1.
The median age at the time of retreatment was 58.9
years (range, 31.0-85.6). The median dose of previous RT
was 45 Gy (range, 20-74), and 20 (64.5%) patients
received conventionally fractionated treatment to a dose
of 45 to 54 Gy. Short-course RT was previously used in 6
patients treated to a dose of 20 to 25 Gy in 5 fractions.6
All previous treatment was delivered with a conven-
tional 4-ﬁeld box technique. The median interval between
the 2 courses of RT was 39.8 months (range, 10.1-307.6).
Of the 31 patients, 22 (71.0%) received reirradiation after
an interval of 5 years, and 18 (58.1%) were symptom-
atic at local recurrence, with 5 patients exhibiting more
than 1 symptom. Symptoms were identiﬁed by retro-
spective review of chart records and most commonly
included pelvic pain (nZ14), rectal bleeding (nZ3),
increased bowel movement frequency (nZ3), pelvic
pressure/obstructive symptoms (nZ2), or urinary symp-
toms (nZ2). The symptomatic response rate was assessed
within three months of completing reirradiation, and
successful palliation was deﬁned as a reduction or com-
plete disappearance of symptoms. Retreatment intent was
neoadjuvant in 9 patients, adjuvant (reirradiation given
after surgery) in 2 patients, and for palliation in 20 pa-
tients. Surgery was generally reserved for patients with an
isolated local recurrence.
Table 1 Patient characteristics




Indication for prior radiation therapy
Rectal/rectosigmoid cancer 27 (87.1%)
Other cancers 4 (12.9%)






Symptomatic at local recurrence
Yes 18 (58.1%)
No 13 (41.9%)
Advances in Radiation Oncology: AprileJune 2016 Reirradiation with IMRT for rectal cancer 95
Reirradiation treatment
All patients were treated with IMRT to a volume
consisting of the gross tumor recurrence plus a planning
target volume margin of 5 to 7 mm. Ninety-ﬁve percent of
the prescriptive dose covered the whole target tumor
volume. Generally, the conformality of treatment plans
was optimized to keep cumulative dose to the femoral
heads under 50 Gy. Because different areas of small
bowel were likely in the pelvis at reirradiation compared
with initial treatment, conformality of treatment was
maximized, although speciﬁc small bowel objectives were
not used.
Over the time of the study, the prescribed dose was
variable. Treatment characteristics are listed in Table 2.
All patients underwent IMRT using either an accelerated
hyperfractionation (39 Gy in 1.5-Gy fractions delivered
twice daily, nZ15) or once-daily fractionation technique
(median dose, 30.4 Gy; range, 27-40 Gy in 15-22 frac-
tions; nZ16). All patients who underwent accelerated
hyperfractionation RT were treated between 2010 and
2013. The median cumulative dose of RT (initial course
plus reirradiation) was 77 Gy (range, 59-113). Radiation
therapy was delivered using 6- to 18-MV photons. Ex-
amples of planning target volume with isodose distribu-
tions are shown in Fig 1. Concurrent chemotherapy was
administered for 25 (80.6%) patients with capecitabine
(nZ11), continuous infusion 5-ﬂuorouracil (5-FU)
(nZ10), bolus 5-FU (nZ1), or other (nZ3).
Table 2 Treatment characteristics
Fractionation schedule
Accelerated twice-daily hyperfractionation 15 (48.4%)
Once daily fractionation 16 (51.6%)
Retreatment site
Rectal/perirectal region 15 (48.4%)




Figure 1 Planning target volume with isodose distributions for a typical case.
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Follow-up
Follow-up was performed by colorectal surgery, radi-
ation oncology, and medical oncology. Interval follow-up
was generally completed every 3 months including
physical examination, routine bloodwork, and cross-
sectional imaging.
Statistical analysis
Statistical analysis was completed in StatView 5.0.1
(SAS Institute Inc.). Acute and late toxicity were graded
using Common Terminology Criteria for Adverse Events,
version 3.0.7 Local progression was deﬁned as any
recurrence in the pelvis or disease progression in the
pelvis detected on radiographic studies or endoscopy. The
rates of freedom from local progression and overall sur-
vival were estimated by Kaplan-Meier methods with log-
rank test considered signiﬁcant between 2 groups at 0.05




The prescribed treatment was completed in 29/31
(93.5%) patients. One patient had treatment discontinued
at 16.5 Gy because of disease progression and 1 patient
had the last treatment fraction omitted, reason not other-
wise speciﬁed. Surgery was performed in 9 (29.0%) pa-
tients and was not performed in 2 patients with
neoadjuvant treatment intent because of distant progres-
sion in 1 and local plus distant progression in the other.
Among the 9 patients undergoing surgery, 2 had complete
removal of all gross tumor with microscopically negative
margins (R0 resection), 6 patients had complete removal
of all gross tumor with microscopically positive margins
(R1 resection), and 1 patient had unknown resection sta-
tus. Among 18 patients with symptoms attributable to
recurrent disease, successful palliation was achieved in
10/18 (55.6%).
Survival and recurrence outcomes
The median follow-up interval was 11.3 months for all
patients and 20.7 months for patients alive at last follow-
up.
Twelve (38.7%) patients developed pelvic local pro-
gression. The 1- and 2-year actuarial rates of freedom
from local progression were 61.3% and 47.3%, respec-
tively (Table 3). The median duration of freedom from
local progression was 23.6 months. There was no statis-
tically signiﬁcant difference in the rates of freedom from
local progression in patients who had surgical resection
compared with those who did not (PZ.238) (Fig 2). The
1-year actuarial rate of freedom from local progression
was 75.0% for patients who had surgical resection and
54.6% for patients who did not (Table 4). There was no
signiﬁcant association between the freedom from local
progression and the retreatment interval (PZ.846), the
freedom from local progression and the retreatment dose
(PZ.440), or the freedom from local progression and
fractionation technique (PZ.286).
There were 19 (61.3%) deaths among the 31 patients.
The 1- and 2-year actuarial overall survival rates were
60.8% and 45.4%, respectively. The median duration of
overall survival was 21.9 months. There was no statisti-
cally signiﬁcant difference in the rates of overall survival
in patients who had surgical resection compared with
those who did not (PZ.0802) (Fig 3). The 1-year overall
survival rate was 66.7% for patients who had surgical
resection and 58.7% for patients who did not.
There was no signiﬁcant association between retreat-
ment interval and overall survival (PZ.811). The 1-year
actuarial overall survival rate was 61.1% for those pa-
tients with a retreatment interval >3 years and 59.8% for
those with a retreatment interval 3 years.
Retreatment dose was not signiﬁcantly associated with
overall survival (PZ.104). The 1-year actuarial overall
survival rate was 71.4% for patients who were treated
with high retreatment dose (median dose, 39 Gy; range,
39-40 Gy) and 38.5% for patients treated with low
retreatment dose (median dose, 30 Gy; range, 27-36 Gy).










Overall survival 60.8 45.4 21.9
Figure 2 Kaplan-Meier estimates of freedom from local pro-
gression in patients who did and did not undergo surgery.
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Fractionation technique was not signiﬁcantly associ-
ated with overall survival (PZ.379). The 1-year actuarial
overall survival rate was 65.5% for patients treated with
accelerated hyperfractionation and 50.0% for patients
treated with once daily fractionation technique.
Toxicity
No patient developed grade 4 acute toxicity and only 1
(3.2%) patient developed grade 3 acute toxicity during
chemoradiation. This patient had grade 3 diarrhea and
required hospitalization. No other patient underwent
hospitalization for acute toxicity. Ten (32.3%) patients
developed grade 2 acute toxicity. The speciﬁc types of
grade 2 acute toxicity included nausea/vomiting in 4 pa-
tients, skin toxicity in 4 patients, and diarrhea in 2 pa-
tients. No patient developed grade 4 late toxicity, and 1
(3.2%) patient developed grade 3 late toxicity. This pa-
tient experienced a sacral insufﬁciency fracture.
Discussion
Local recurrence in rectal cancer is a challenge, with
salvage surgery preferred but not always possible. Reir-
radiation in recurrent pelvic disease may help downstage
tumors to make surgical resection possible and improves
palliative symptom control. In this study, reirradiation
was well-tolerated, with a rate of a grade 2 acute toxicity
of 32.3%, grade 3 acute toxicity of 3.2% (1 patient), grade
3 late toxicity of 3.2% (1 patient), and no grade 4 acute or
late toxicities. Using a median retreatment dose of 39 Gy,
the median duration of freedom from local progression
was 23.6 months, the median duration of overall survival
was 21.9 months, and the symptomatic response rate was
55.6%. Table 5 highlights the results of this study in the
context of prior studies of rectal cancer reirradiation.
Reirradiation up to 30 Gy, even with chemotherapy,
has been shown to be safe for palliation and possible cure
for resectable locally recurrent rectal cancer, and doses up
to 40 Gy can be used for limited volumes.9 Mohiuddin
et al published a study of 103 patients with recurrent
rectal adenocarcinoma who underwent reirradiation (me-
dian dose, 34.8 Gy; range, 15-49.2 Gy) with concurrent
continuous infusion 5-FU.10 The median cumulative dose
was 85.8 Gy (range, 70.6-108), with 40 patients treated
with 1.2-Gy fractions twice daily, 63 patients treated with
1.8-Gy fractions daily, and 34 patients undergoing sur-
gery. The rates of grade 3 to 4 acute and late toxicities
were 28.2% and 21.4%, respectively. The median overall
survival was 26 months and the 5-year actuarial survival
rate was 19%. For patients undergoing surgical resection,
the median overall survival was 44 months and 5-year
actuarial survival rate was 22%. The high rates of acute
toxicity in this study may be due to larger ﬁeld sizes or
higher total doses. Mohiuddin et al also postulated that
reirradiation dose may be titrated based on interval to
reirradiation. A reirradiation dose of 35 Gy was recom-
mended in their series if the interval to reirradiation is
shorter than 12 months, and a reirradiation dose of 50 to
55 Gy if the interval to reirradiation is longer than 36
months.
Valentini et al reported a multicenter phase 2 study of
preoperative hyperfractionated reirradiation in 59 patients
for locally recurrent rectal cancer.11 Patients were treated
with a dose of 40.8 Gy in 1.2-Gy fractions twice daily and
with protracted venous infusion 5-FU. The median
Table 4 Pelvic control and overall survival rates by sur-
gery, retreatment interval, and retreatment dose
Parameter 1-y rate (%) P value
Freedom from local progression
Surgical resection 75.0 .238
No surgical resection 54.6
Freedom from local progression
Retreatment 3 y 59.3 .846
Retreatment >3 y 61.4
Freedom from local progression
High retreatment dose 56.2 .440
Low retreatment dose 71.6
Freedom from local progression
Accelerated hyperfractionation 43.2 .286
Once- daily fractionation 68.2
Overall survival
Surgical resection 66.7 .0802
No surgical resection 58.7
Overall survival
Retreatment 3 y 59.8 .811
Retreatment >3 y 61.1
Overall survival
High retreatment dose 71.4 .104
Low retreatment dose 38.5
Overall survival
Accelerated hyperfractionation 65.5 .379
Once-daily fractionation 50.0
Figure 3 Kaplan-Meier estimates of overall survival in pa-
tients who did and did not undergo surgery.
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cumulative dose was 90.8 Gy (range, 70.8-95.8), and 39
patients underwent surgery. The rates of grade 3 to 4
acute and late toxicities were 5.1% and 11.9%, respec-
tively. The 3- and 5-year actuarial rates of local control
were 59% and 39%, respectively. The median overall
survival was 42 months and the 5-year actuarial survival
rate was 39%. For the 21 patients undergoing R0 (no
residual tumor) resection, the 5-year actuarial survival rate
was 66.8%.
Lingareddy et al reported a study of palliative reirra-
diation in 52 patients with recurrent rectal cancer.12
Twenty-two patients received 30 Gy in 1.2-Gy fractions
twice daily and 30 patients received 30.6 Gy in 1.8- to
2.0-Gy fractions daily. The median reirradiation dose was
30.6 Gy and median cumulative dose was 84.4 Gy (range,
66.6-104.9). Ninety percent of patients received concur-
rent 5-FU. The median overall survival was 12 months
and the 2- and 3-year overall actuarial rates were 25% and
14%, respectively. The rate of grade 3 acute toxicity was
30.7%, and no patient experienced grade 4 acute toxicity.
The rate of grade 3 late toxicity was 23.1%, and 9.6% of
patients experienced grade 4 late toxicity. Patients treated
with hyperfractionated RT had a late toxicity rate of 18%
compared with 47% with once-daily fractions (P < .05).
On logistic regression analysis, hyperfractionated RT
was signiﬁcantly associated with reduced late toxicity
(P < .04).
In Das et al, 94% of patients received accelerated
hyperfractionation (39 Gy in 1.5-Gy fractions delivered
twice daily). In Ng et al, 70% of patients received a
reirradiation dose of 39.6 Gy in 1.8-Gy fractions daily.
Although this dose fractionation regimen is higher than
those previously described, it was deemed appropriate
because of the median survival of 19 months, low rate of
late toxicity, and practicality over hyperfractionated
regimens.
In 2014, Guren et al reported a systematic review of
reirradiation of locally recurrent rectal cancer.13 The
median initial radiation dose was 50.4 Gy, with a median
time of 8 to 30 months before reirradiation. The median
reirradiation dose was 30 to 40 Gy to the gross tumor
volume, which was mostly administered using hyper-
fractionation (1.2-1.5 Gy twice daily) or once-daily
fractionation (1.8-Gy) technique. Median survival was 39
to 60 months in resected patients and 12 to 16 months in
patients treated palliatively. Successful palliation was re-
ported in 82% to 100% of patients, acute toxicities were
reported in 9% to 20% of patients, and late toxicities were
insufﬁciently reported.
In the current study, 15 patients received accelerated
hyperfractionation (39 Gy in 1.5-Gy fractions delivered
twice daily), whereas 16 patients received once-daily
fractionation with a median dose of 30.4 Gy (range, 27-
40) in 15 to 22 fractions. Overall treatment was well-
tolerated in our group, and acute and late toxicities rates
were favorable. However, 1- and 2-year local control was
suboptimal. The low toxicity but suboptimal tumor con-
trol observed in the current series, which incorporated
IMRT, suggests that greater reirradiation doses should be
considered. Koom et al showed that in patients not un-
dergoing surgery, reirradiation doses exceeding 50 Gyab10
(equivalent dose in 2 fractions, a/bZ10) signiﬁcantly
increased the inﬁeld progression-free survival
(PZ.005).14
There are certain inherent limitations to this retro-
spective study, including limited sample size, although
our study also has several strengths. Toxicity rates may
have been underestimated because they were based on
hospital records and physician rather than direct patient-
reported outcomes. Although patient-reported quality of
life outcomes would be preferable in this regard, based on
physician reporting, the majority of patients that were
symptomatic at presentation were palliated successfully
by the described regimen. In addition to IMRT, the use of
short-course RT as initial preoperative treatment may
have affected the low rate of toxicity observed in our
series. Finally, the date of retreatment was covariate to
treatment dose and chemotherapy, which may confound
the improved overall survival rates for patients treated
with higher reirradiation doses, who also received more
modern systemic therapy. This is likely mitigated by the
relatively narrow and modern time window of patient
treatments reviewed, from 2004 to 2013. In spite of these
limitations, our results suggest that toxicity is acceptably
low for rectal cancer reirradiation using IMRT, which
allows for precise dose delivery to limited target volumes.
Table 5 Comparison of prior studies of rectal cancer reirradiation
Study N MRD (Gy) MCD (Gy) Acute toxicity Late toxicity Median OS (mo)
G3 (%) G4 (%) G3 (%) G4 (%)
Das et al 50 39 89 4 0 24 2 26
Lingareddy et al 52 30.6 84.4 31 0 23 10 12
Mohiuddien et al 103 34.8 85.8 22 6 17 4 26
Ng et al 56 39.6 87.3 13 0 2 0 19
Valentini et al 59 40.8 90.8 5.1 0 12 0 42
Youssef et al 31 39 77 3 0 3 0 22
MCD, median cumulative dose; MRD, median retreatment dose.
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In addition, hyperfractionation is used to reduce late ef-
fects of reirradiation, and although this is most important
for patients with curative intent, hyperfractionated RT
may still have a role in palliative treatment using dose-
escalated regimens. However, for some patients treated
with palliative intent, once-daily RT may be optimal
depending on their performance status and extent of
metastatic disease, along with practicality and conve-
nience. Given successful palliation, low observed toxicity,
but suboptimal tumor control rates in particular for
inoperable patients, our current institutional practice is for
reirradiation of 39 Gy (1.5 Gy twice-daily fractionation)
in the preoperative setting and 45 Gy (1.5 Gy twice-daily
fractionation) for patients not planned for salvage surgery.
Conclusion
In summary, rectal cancer reirradiation using IMRT is
well tolerated in the setting of prior pelvic RT. Given
signiﬁcant risk of local progression for patients not un-
dergoing surgery, further dose escalation may be war-
ranted for such patients with life expectancy exceeding 1
year.
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